These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12725788)

  • 1. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells.
    Wang RF
    Methods; 2003 Mar; 29(3):227-35. PubMed ID: 12725788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cloning and characterization of MHC class I- and II-restricted tumor antigens recognized by T cells.
    Wang RF
    Curr Protoc Immunol; 2009 Feb; Chapter 20():20.10.1-20.10.29. PubMed ID: 19235768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
    Zeng G
    J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
    Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
    Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
    Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
    J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
    Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
    Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
    Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.
    Wang RF
    Trends Immunol; 2001 May; 22(5):269-76. PubMed ID: 11323286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation.
    Spierings E; Vermeulen CJ; Vogt MH; Doerner LE; Falkenburg JH; Mutis T; Goulmy E
    Lancet; 2003 Aug; 362(9384):610-5. PubMed ID: 12944060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct mapping of MHC class II epitopes.
    Milosevic S; Behrends U; Christoph H; Mautner J
    J Immunol Methods; 2005 Nov; 306(1-2):28-39. PubMed ID: 16168435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Human Antigen-Specific CD4
    Kong YY; Kwok WW
    Methods Mol Biol; 2019; 1988():375-386. PubMed ID: 31147953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated Listeria monocytogenes carrier strains can deliver an HIV-1 gp120 T helper epitope to MHC class II-restricted human CD4+ T cells.
    Guzmán CA; Saverino D; Medina E; Fenoglio D; Gerstel B; Merlo A; Li Pira G; Buffa F; Chakraborty T; Manca F
    Eur J Immunol; 1998 Jun; 28(6):1807-14. PubMed ID: 9645361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplex mapping of CD4 T cell epitopes using class II tetramers.
    Yang J; James EA; Huston L; Danke NA; Liu AW; Kwok WW
    Clin Immunol; 2006 Jul; 120(1):21-32. PubMed ID: 16677863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
    Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
    Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of human CD4 helper T cell responses against Aurora kinase A.
    Kobayashi H; Azumi M; Hayashi S; Sato K; Aoki N; Kimura S; Kakizaki H; Nagato T; Harabuchi Y; Tateno M; Celis E
    Cancer Immunol Immunother; 2010 Jul; 59(7):1029-39. PubMed ID: 20182874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.
    Oyarzun P; Ellis JJ; Gonzalez-Galarza FF; Jones AR; Middleton D; Boden M; Kobe B
    Vaccine; 2015 Mar; 33(10):1267-73. PubMed ID: 25629524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.